Citadel Advisors
BMY.RT

Citadel Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Citadel Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,952,625
Closed – – 14096
2020
Q4 		$0 Buy
10,952,625
+3,777,773
+53% +$8.05M ﹤0.01% 11826
2020
Q3 		$16.1M Sell
7,174,852
-2,779,405
-28% -$7.94M ﹤0.01% 1762
2020
Q2 		$35.6M Sell
9,954,257
-12,589,085
-56% -$45.4M 0.01% 1019
2020
Q1 		$85.7M Buy
22,543,342
+9,369,239
+71% +$30.9M 0.04% 397
2019
Q4 		$39.7M Buy
+13,174,103
New +$34.3M 0.02% 922

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Citadel Advisors's BMY.RT Position: Q1 2021 in Review

Citadel Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,952,625 shares.

Citadel Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $85.7M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Citadel Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Citadel Advisors sold 10,952,625 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Citadel Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Citadel Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $85.7M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.